8-K: Silexion Selects CRO for SIL204 Phase 2/3 Trials

Silexion Therapeutics announced the selection of AMS Advanced Medical Services GmbH as its Contract Research Organization to support upcoming Phase 2/3 clinical trials for its lead candidate, SIL204.

Summary

• Silexion Therapeutics Corp. (NASDAQ: SLXN) has selected AMS Advanced Medical Services GmbH (AMS) as its Contract Research Organization (CRO).
• AMS will support the upcoming Phase 2/3 clinical trials for SIL204, Silexion's next-generation siRNA candidate targeting KRAS-driven solid tumor cancers.
• AMS brings over 28 years of drug development experience and expertise in Phase 3 oncology trials.
• Regulatory submissions are planned for Q4 2025 (Israel Ministry of Health) and Q1 2026 (European Union).
• Phase 2/3 clinical trials are expected to commence in the first half of 2026.
• SIL204 recently demonstrated up to 97% inhibition rates in preclinical studies for pancreatic cancer cells (KRAS Q61H mutations), approximately 90% inhibition in colorectal cancer cells, and significant dose-dependent activity in lung cancer cell lines.
• The trial will evaluate a dual-route administration strategy (intratumoral and systemic) for locally advanced pancreatic cancer (LAPC).

Sentiment

Score: 8

Explanation: The announcement of selecting a highly experienced CRO for pivotal Phase 2/3 trials, coupled with strong preclinical data for SIL204 and a clear timeline for regulatory submissions and trial commencement, represents a significant positive step for Silexion Therapeutics. This de-risks the clinical development pathway and builds confidence in the company's ability to advance its lead candidate. The explicit mention of future capital requirements is a standard disclosure for a clinical-stage biotech but does not detract from the positive operational progress.

Positives

• Selection of an experienced CRO (AMS) with over 28 years of drug development and Phase 3 oncology trial expertise is a critical step forward for SIL204's clinical development.
• Preclinical results for SIL204 showed strong efficacy, including up to 97% inhibition in pancreatic cancer cells and approximately 90% inhibition in colorectal cancer cells.
• SIL204 has demonstrated activity against multiple KRAS mutations (G12D, G12V, G12R, Q61H, G13D), indicating broad potential.
• The dual-route administration strategy (intratumoral and systemic) is innovative and supported by preclinical data showing reduction in primary tumor growth and metastatic spread.
• A manufacturing partnership with Catalent is already in place, establishing a comprehensive foundation for the clinical program.
• The company's first-generation product showed a positive trend in a Phase 2a clinical trial.

Risks

• Ability to successfully complete preclinical studies and initiate clinical trials.
• Uncertainties regarding Silexion's strategy, future operations, financial position, projected costs, prospects, and plans.
• Impact of the regulatory environment and complexities in compliance.
• Uncertainties regarding future partnerships or other relationships with third parties.
• Future capital requirements and the ability to obtain additional capital.
• Ability to maintain Nasdaq listing.
• Other risks and uncertainties detailed in the Company's SEC filings, including the Quarterly Report on Form 10-Q for the quarter and six months ended June 30, 2025.

Future Outlook

Silexion Therapeutics anticipates finalizing its partnership agreement with AMS shortly. The company plans regulatory submissions to the Israel Ministry of Health in Q4 2025 and to the European Union in Q1 2026, with Phase 2/3 clinical trials for SIL204 expected to commence in the first half of 2026. The collaboration will focus on regulatory strategy, clinical trial design, site selection, management, and data analysis for the planned study evaluating SIL204's dual-route administration approach in locally advanced pancreatic cancer patients.

Management Comments

• "Selecting AMS as our CRO partner represents a critical milestone as we advance SIL204 toward clinical development." Ilan Hadar, Chairman and CEO of Silexion Therapeutics.
• "This partnership brings the deep oncology expertise and regulatory knowledge essential for executing our dual-route administration strategy effectively." Ilan Hadar.
• "AMS's strong experience with Phase 3 oncology trials brings a unique level of proven expertise which we believe will bolster our clinical program." Ilan Hadar.
• "With SIL204 having recently demonstrated up to 97% inhibition rates in preclinical studies and our manufacturing partnership with Catalent already in place, we are building the comprehensive foundation needed to bring this potentially transformative RNAi therapy to patients with KRAS-driven cancers." Ilan Hadar.
• "We are excited and honored to have been selected as the CRO to manage Silexion's pivotal study." Dr. Christian Carls, Managing Director of AMS.
• "AMS provides Silexion a global CRO with extensive experience across a wide range of oncology indications and particularly deep expertise in pancreatic cancer." Dr. Christian Carls.
• "Partnering with Silexion provides a rare and meaningful opportunity to contribute to the development of an important and potentially disease-altering treatment." Dr. Christian Carls.

Industry Context

The selection of a Contract Research Organization (CRO) is a standard and crucial step in the biotechnology industry for advancing drug candidates from preclinical stages to human clinical trials. Silexion's focus on KRAS-driven cancers with an RNAi therapy positions it in a highly competitive and innovative segment of oncology, where significant unmet medical needs exist. The dual-route administration strategy for pancreatic cancer, a particularly challenging indication, highlights an attempt to differentiate within the crowded oncology pipeline. The involvement of an experienced CRO like AMS, with a track record in Phase 3 oncology trials, suggests a commitment to rigorous clinical development, which is critical for regulatory success and investor confidence in the biotech sector.

Comparison to Industry Standards

• The selection of an experienced CRO like AMS, with 28 years of experience and Phase 3 oncology trial expertise, aligns with industry best practices for managing complex international clinical trials, similar to how larger pharmaceutical companies like Pfizer or Novartis engage top-tier CROs such as IQVIA or PPD for their pivotal studies.
• SIL204's preclinical inhibition rates of up to 97% in pancreatic cancer cells and 90% in colorectal cancer cells are highly promising, potentially comparable to early-stage data from other leading KRAS inhibitors like Amgen's Lumakras (sotorasib) or Mirati Therapeutics' Krazati (adagrasib), which also showed significant tumor shrinkage in clinical trials, though direct comparison to preclinical inhibition rates is not a clinical outcome.
• The dual-route administration strategy for locally advanced pancreatic cancer is an innovative approach, seeking to overcome the challenges of drug delivery and efficacy in a notoriously difficult-to-treat cancer, similar to advanced delivery methods explored by companies like Ipsen or AstraZeneca in their oncology pipelines.

Stakeholder Impact

• Shareholders: Positive impact due to advancement of the lead drug candidate into pivotal clinical trials, potentially increasing company valuation and future prospects.
• Patients: Potential for a new, transformative RNAi therapy for KRAS-driven cancers, particularly locally advanced pancreatic cancer, addressing a significant unmet medical need.
• Employees: Continued progress in the company's pipeline provides stability and purpose, potentially attracting new talent.
• Regulatory Authorities: Will be involved in reviewing submissions and overseeing clinical trials, ensuring compliance and patient safety.

Next Steps

• Finalize the partnership agreement with AMS Advanced Medical Services GmbH.
• Submit regulatory applications to the Israel Ministry of Health in Q4 2025.
• Submit regulatory applications to the European Union in Q1 2026.
• Commence Phase 2/3 clinical trials for SIL204 in the first half of 2026.
• Execute the planned Phase 2/3 study evaluating SIL204's dual-route administration approach in patients with locally advanced pancreatic cancer.

Key Dates

Recommendation

The selection of a highly experienced Contract Research Organization (CRO) like AMS, with a proven track record in Phase 3 oncology trials, is a critical de-risking event for Silexion Therapeutics. This partnership provides a clear pathway for the advancement of SIL204 into pivotal Phase 2/3 clinical trials, supported by strong preclinical data showing high inhibition rates against multiple KRAS mutations in challenging cancers. The established timeline for regulatory submissions and trial commencement in H1 2026 provides concrete milestones. For a clinical-stage biotech, successfully moving a lead candidate into late-stage trials with a robust operational partner significantly enhances its investment profile, suggesting a 'buy' recommendation for investors looking for growth in the oncology biotech sector, despite the inherent risks of drug development.

Keywords

Silexion Therapeutics, SIL204, RNAi therapy, KRAS-driven cancers, Phase 2/3 clinical trials, Contract Research Organization, AMS Advanced Medical Services, Oncology, Pancreatic cancer, Colorectal cancer, Lung cancer, siRNA, Biotechnology, Clinical stage, Drug development